157 related articles for article (PubMed ID: 8800968)
1. Sumatriptan use in a large group-model health maintenance organization.
Greiner DL; Addy SN
Am J Health Syst Pharm; 1996 Mar; 53(6):633-8. PubMed ID: 8800968
[TBL] [Abstract][Full Text] [Related]
2. Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
Gershovich OE; Billups SJ; Delate T; Hoffman CK; Carroll N
J Manag Care Pharm; 2006 Apr; 12(3):246-53. PubMed ID: 16623609
[TBL] [Abstract][Full Text] [Related]
3. Cost benefit of sumatriptan to an employer.
Legg RF; Sclar DA; Nemec NL; Tarnai J; Mackowiak JI
J Occup Environ Med; 1997 Jul; 39(7):652-7. PubMed ID: 9253726
[TBL] [Abstract][Full Text] [Related]
4. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes.
Cohen JA; Beall D; Beck A; Rawlings J; Miller DW; Clements B; Pait DG; Batenhorst A
Clin Ther; 1999 Jan; 21(1):190-204. PubMed ID: 10090435
[TBL] [Abstract][Full Text] [Related]
5. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.
Lofland JH; Johnson NE; Batenhorst AS; Nash DB
Arch Intern Med; 1999 Apr; 159(8):857-63. PubMed ID: 10219932
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial.
Schulman EA; Cady RK; Henry D; Batenhorst AS; Putnam DG; Watson CB; O'Quinn SO
Mayo Clin Proc; 2000 Aug; 75(8):782-9. PubMed ID: 10943230
[TBL] [Abstract][Full Text] [Related]
7. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine.
Mushet GR; Miller D; Clements B; Pait G; Gutterman DL
Headache; 1996 Mar; 36(3):137-43. PubMed ID: 8984084
[TBL] [Abstract][Full Text] [Related]
8. Sumatriptan. An updated review of its use in migraine.
Perry CM; Markham A
Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
[TBL] [Abstract][Full Text] [Related]
9. Impact of sumatriptan on clinic utilization and costs of care in migraineurs.
Litaker DG; Solomon GD; Genzen JR
Headache; 1996 Oct; 36(9):538-41. PubMed ID: 8916561
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sumatriptan in a managed care population.
Legg RF; Sclar DA; Nemec NL; Tarnai J; Mackowiak JI
Am J Manag Care; 1997 Jan; 3(1):117-22. PubMed ID: 10169243
[TBL] [Abstract][Full Text] [Related]
11. HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan.
Goldfarb SD; Duncan BS; Dans PE; Sloan AS
Am J Health Syst Pharm; 1999 Nov; 56(21):2206-10. PubMed ID: 10565699
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences.
Cohen JA; Beall DG; Miller DW; Beck A; Pait G; Clements BD
Fam Med; 1996 Mar; 28(3):171-7. PubMed ID: 8900548
[TBL] [Abstract][Full Text] [Related]
13. Costs and outcomes of early versus delayed migraine treatment with sumatriptan.
Halpern MT; Lipton RB; Cady RK; Kwong WJ; Marlo KO; Batenhorst AS
Headache; 2002; 42(10):984-99. PubMed ID: 12453030
[TBL] [Abstract][Full Text] [Related]
14. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.
Caro G; Getsios D; Caro JJ; Raggio G; Burrows M; Black L
Cephalalgia; 2001 Feb; 21(1):12-9. PubMed ID: 11298658
[TBL] [Abstract][Full Text] [Related]
15. Using pretreatment quality of life perceptions to predict response to sumatriptan in migraineurs.
Litaker DG; Solomon GD; Genzen JR
Headache; 1997; 37(10):630-4. PubMed ID: 9439083
[TBL] [Abstract][Full Text] [Related]
16. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
Géraud G; Valette C
Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800
[TBL] [Abstract][Full Text] [Related]
17. Triptan therapy impacts health and productivity.
Weaver MB; Mackowiak JI; Solari PG
J Occup Environ Med; 2004 Aug; 46(8):812-7. PubMed ID: 15300133
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic evidence and considerations for triptan treatment of migraine.
Caro JJ; Getsios D
Expert Opin Pharmacother; 2002 Mar; 3(3):237-48. PubMed ID: 11866674
[TBL] [Abstract][Full Text] [Related]
19. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine.
Biddle AK; Shih YC; Kwong WJ
Pharmacotherapy; 2000 Nov; 20(11):1356-64. PubMed ID: 11079284
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Zhang L; Hay JW
CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
